Healthy
Conditions
Keywords
Phase I, Japanese healthy volunteer, AZD5069
Brief summary
This is a study in Japanese healthy volunteers to determine the safety and tolerability of the compound, AZD5069. It will also assess how the body handles the drug and how it responds to the drug following single and multiple doses up to 11 days.
Interventions
DRUGAZD5069
Oral suspension
DRUGPlacebo
Oral suspension
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Japanese subjects with suitable veins for cannulation or repeated venepuncture. * Have a body mass index (BMI) between 17 and 27 kg/m2 and a body weight between 45 and 80 kg * Male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosing until 3 months after the last dose of investigational product
Exclusion criteria
* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. * History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs * Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 4 weeks of the first administration of investigational product. * Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events, electrocardiograms (ECGs), laboratory variables, blood pressure, pulse rate, body temperature, QT interval and continuous cardiac monitoring using telemetry | From screening period to follow-up visit 42 days (Maximum) |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of ex vivo GROa stimulated CD11b expression on neutrophils in whole blood | Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose |
| Measurement of the effect of AZD5069 on blood cells | Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose |
| Pharmacokinetic profile: concentration of AZD5069 in blood | Baselines at Visit 1 or pre-dose Day 1, assessments Visit 2, post-dose until 96hr post final dose. Follow up assessments at Visit 3. Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose. |
Countries
United Kingdom
Outcome results
None listed